Naratriptan Eg (Naratriptan)

Naratriptan belongs to the Triptan class and is indicated for the acute treatment of migraine-related disorders.

• Migraine: provides rapid relief of headache pain and associated symptoms when taken early in an attack.
• Migraine with aura: alleviates headache and aura‑related discomfort during an acute episode.
• Acute episodic migraine: aborts migraine attacks and reduces the need for additional medication.

• Naratriptan selectively activates serotonin 5‑HT1B and 5‑HT1D receptors on intracranial blood vessels and trigeminal nerve endings. This activation causes cranial vasoconstriction and inhibits the release of vasoactive neuropeptides, thereby reducing neurogenic inflammation and interrupting pain transmission associated with migraine attacks.

Common Side Effects

• Nausea: mild to moderate stomach upset after dosing.
• Dizziness: transient light‑headedness, especially when standing quickly.
• Fatigue: feeling unusually tired or weak.
• Dry mouth: reduced salivation causing throat discomfort.
• Tingling or numbness: peripheral sensations in the hands or feet.

Serious or Rare Side Effects

• Chest discomfort or tightness: may indicate coronary vasospasm and requires immediate medical attention.
• Serotonin syndrome: rare but potentially life‑threatening reaction when combined with other serotonergic agents.
• Severe allergic reaction: rash, swelling, or difficulty breathing indicating anaphylaxis.

Before using Naratriptan, consider the following precautions:

• Cardiovascular History: assess for coronary artery disease, uncontrolled hypertension, or cerebrovascular disorders.
• Concomitant Medications: avoid other triptans, ergot alkaloids, or serotonergic drugs without medical guidance.
• Allergies: confirm no hypersensitivity to naratriptan or any tablet excipients.
• Pregnancy and Lactation: use only if the potential benefit justifies the potential risk to the fetus or infant.
• Driving and Machinery: exercise caution if dizziness or fatigue occurs after dosing.
• Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Naratriptan may interact with several drug classes.

Major Interactions (Avoid)

• Other triptans: additive vasoconstrictive effects increase cardiovascular risk.
• Ergot alkaloids: combined use can cause severe vasospasm.
• Monoamine oxidase inhibitors (MAOIs): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• SSRIs, SNRIs, or other serotonergic agents: monitor for signs of serotonin excess.
• CYP1A2 inhibitors (e.g., fluvoxamine): may raise naratriptan plasma concentrations.
• CYP3A4 inducers (e.g., carbamazepine): may reduce therapeutic effectiveness.